Clinical Trial Update: LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) [Phase 4]

View source ↗

Summary

Phase 4 trial LAM07 completed evaluating a risk-adapted consolidation strategy that included Gemtuzumab ozogamicin for patients with acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Mylotarg (gemtuzumab ozogamicin)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Acute Myeloblastic Leukemia | Phase 4 | Status: COMPLETED